On October 7, 2011, Cephalon, Inc. (the Company) and Teva Pharmaceutical Industries Ltd. (Teva) issued a press release announcing that the U.S. Federal Trade Commission has accepted the proposed consent order in connection with the pending acquisition of the Company by Teva and granted early termination of the Hart Scott Rodino waiting period. The Company hereby incorporates by reference the press release dated October 7, 2011, attached hereto as Exhibit 99.1 and made a part of this Item 8.01.